SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses.
Adult
Aged
Antibodies, Neutralizing
/ analysis
Antibodies, Viral
/ analysis
BNT162 Vaccine
/ administration & dosage
Cohort Studies
Female
HEK293 Cells
Humans
Immunization Schedule
Immunization, Secondary
/ methods
Male
Middle Aged
Quebec
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ immunology
Time Factors
Vaccination
/ methods
Vaccine Potency
Vaccines, Synthetic
/ administration & dosage
Young Adult
mRNA Vaccines
/ administration & dosage
COVID-19
Coronavirus
Omicron
SARS-CoV-2
delayed mRNA vaccine regimen
humoral responses
neutralization
spike glycoproteins
variants of concern
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
01 03 2022
01 03 2022
Historique:
received:
21
12
2021
revised:
25
01
2022
accepted:
02
02
2022
pubmed:
27
2
2022
medline:
11
3
2022
entrez:
26
2
2022
Statut:
ppublish
Résumé
Continuous emergence of SARS-CoV-2 variants of concern (VOCs) is fueling the COVID-19 pandemic. Omicron (B.1.1.529) rapidly spread worldwide. The large number of mutations in its Spike raise concerns about a major antigenic drift that could significantly decrease vaccine efficacy and infection-induced immunity. A long interval between BNT162b2 mRNA doses elicits antibodies that efficiently recognize Spikes from different VOCs. Here, we evaluate the recognition of Omicron Spike by plasma from a cohort of SARS-CoV-2 naive and previously infected individuals who received their BNT162b2 mRNA vaccine 16 weeks apart. Omicron Spike is recognized less efficiently than D614G, Alpha, Beta, Gamma, and Delta Spikes. We compare with plasma activity from participants receiving a short (4 weeks) interval regimen. Plasma from individuals of the long-interval cohort recognize and neutralize better the Omicron Spike compared with those who received a short interval. Whether this difference confers any clinical benefit against Omicron remains unknown.
Identifiants
pubmed: 35216664
pii: S2211-1247(22)00153-X
doi: 10.1016/j.celrep.2022.110429
pmc: PMC8823958
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
Vaccines, Synthetic
0
mRNA Vaccines
0
spike protein, SARS-CoV-2
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
110429Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests A.F. has filed a provisional patent application on the anti-Spike monoclonal antibody CV3-25.
Références
Viruses. 2021 Dec 21;14(1):
pubmed: 35062211
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Cell. 2021 May 13;184(10):2605-2617.e18
pubmed: 33831372
Cell. 2021 Jul 22;184(15):3936-3948.e10
pubmed: 34192529
J Infect. 2021 Apr;82(4):e8-e10
pubmed: 33472093
Nature. 2021 Dec;600(7889):512-516
pubmed: 34544114
Front Immunol. 2022 Jan 24;12:830527
pubmed: 35140714
Cell Rep Med. 2020 Oct 20;1(7):100126
pubmed: 33015650
Cell Rep. 2021 Jul 13;36(2):109353
pubmed: 34237283
J Biol Chem. 2021 Oct;297(4):101151
pubmed: 34478710
Immunity. 2021 Sep 14;54(9):2143-2158.e15
pubmed: 34453881
Elife. 2020 Oct 28;9:
pubmed: 33112236
JAMA. 2022 Jan 18;327(3):279-281
pubmed: 34860253
Science. 2021 Feb 19;371(6531):850-854
pubmed: 33495308
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Science. 2021 Feb 19;371(6531):823-829
pubmed: 33495307
Lancet Reg Health Eur. 2022 Jan;12:100252
pubmed: 34729548
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Euro Surveill. 2021 Jan;26(3):
pubmed: 33478621
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Virology. 2021 Nov;563:134-145
pubmed: 34536797
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
Cell Rep. 2022 Jan 11;38(2):110210
pubmed: 34971573
Clin Infect Dis. 2022 Nov 30;75(11):1980-1992
pubmed: 35438175
mBio. 2020 Oct 16;11(5):
pubmed: 33067385
N Engl J Med. 2022 Feb 10;386(6):599-601
pubmed: 35030645
Cell Host Microbe. 2022 Jan 12;30(1):97-109.e5
pubmed: 34953513
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Cell Rep Med. 2021 Jun 15;2(6):100290
pubmed: 33969322
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Emerg Microbes Infect. 2022 Dec;11(1):1-5
pubmed: 34890524
Cell Rep. 2021 Mar 2;34(9):108790
pubmed: 33596407
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Nat Commun. 2021 Jul 7;12(1):4196
pubmed: 34234131
Science. 2021 Mar 25;:
pubmed: 33766944
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Cell Host Microbe. 2021 Jul 14;29(7):1137-1150.e6
pubmed: 34133950